Roots Analysis has done a detailed study on Neoantigen Targeted Therapies, 2019-2030, covering key aspects of the industry’s evolution and
identifying potential future growth opportunities.
To order this 320+ page report,
which features 110+ figures and 140+ tables, please visit this link
Key Market Insights
§ Presently, over 150 neoantigen targeted therapies are being
evaluated for advanced cancer indications and are designed for delivery via
different routes of administration
§ Several molecules are in early stages of clinical
development; based on delivery strategies, variety of vaccines and
immunotherapies have been established for targeting personalized and shared
antigens
§ Over the years, more than 6,000 patents related to
neoantigens and affiliated therapies have been granted / filed; this is
indicative of the heightened pace of research in this field
§ Both industry and academic players are contributing to the
innovation, which is evident across published scientific literature focused on
multiple targeted therapies for a myriad of cancer indications
§ Several investors, having realized the untapped opportunity
within this emerging segment of cancer immunotherapy, have invested over USD 7
billion across 150 instances in the period between 2014 and 2019
§ The increasing traction in this field is also reflected in
the partnership activity; deals inked in the recent past focused on a diverse
range of therapies, involving both international and indigenous stakeholders
§ The market will receive the required impetus after approval
of the first neoantigen targeted therapy; the future growth is likely to be
driven by the successful clinical outcomes of the late-stage molecules
§ In fact, opinions from industry experts confirm the vast
potential of this segment of cancer immunotherapy, capable of targeting
personalized / off-the-shelf tumour antigens with multiple types of vaccines
and therapies
For more information, please visit https://www.rootsanalysis.com/reports/view_document/neoantigen-targeted-therapies-market-2019-2030/257.html
Table of Contents
1. PREFACE
1.1.
Scope of the Report
1.2.
Research Methodology
1.3.
Chapter Outlines
2. EXECUTIVE
SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Concept of Immunotherapy
3.3. History of Cancer Immunotherapy
3.4. Limitations of Cancer Immunotherapy
3.5. Targeting Tumor-Specific Neoantigens
3.5.1. Types of Neoantigens
3.5.2. Role of Neoantigens in Cancer Immunotherapy
3.5.3. Neoantigen Targeted Therapies
3.5.3.1. Identification and Selection of Neoantigens
3.5.3.2. Delivery of Neoantigen Targeted Therapies
3.6. Key Challenges and Future Perspectives
Press
Release: Variation 2 (Format 3)
4. MARKET
OVERVIEW
4.1. Chapter Overview
4.2. Neoantigen Targeted Therapies: Marketed
and Development Pipeline
4.3. Neoantigen Targeted Therapies: Pipeline
Analysis
4.3.1. Analysis by Phase of Development
4.3.2. Analysis by Type of Molecule
4.3.3. Analysis by Type of Immunotherapy
4.3.4. Analysis by Type of Therapy
4.3.5. Analysis by Route of Administration
4.3.6. Analysis by Target Disease Indication
4.3.7. Analysis by Type of Neoantigen
4.3.8. Analysis by Line of Therapy
4.3.9. Funnel Analysis: Analysis by Phase of Development, Type of
Immunotherapy and Type of Therapy
4.3.10. Heptagon Representation: Analysis by Phase of
Development and Route of Administration
4.4. Neoantigen Targeted Therapies: List of
Drug Developers
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Company Size and Geographical
Location
4.4.3. Leading Developers
4.4.4. Analysis by Geography
4.5 Grid Analysis: Analysis by Target Disease
Indication, Company Size and Location
5. COMPANY
PROFILES: NEOANTIGEN TARGETED THERAPIES
5.1. Chapter Overview
5.2. Bavarian Nordic
5.2.1. Company Overview
5.2.2. Financial Information
5.2.3. Neoantigen Targeted Therapies Portfolio
5.2.4. Recent Collaborations
5.2.5. Future Outlook
5.3. Genocea Biosciences
5.3.1. Company Overview
5.3.2. Financial Information
5.3.3. Neoantigen Targeted Therapies Portfolio
5.3.4. Recent Collaborations
5.3.5. Future Outlook
5.4. Gradalis
5.4.1. Company Overview
5.4.2. Neoantigen Targeted Therapies Portfolio
5.4.3. Recent Collaborations
5.4.4. Future Outlook
5.5. Immunicum
5.5.1. Company Overview
5.5.2. Financial Information
5.5.3. Neoantigen Targeted Therapies Portfolio
5.5.4. Recent Collaborations
5.5.5. Future Outlook
5.6. Immunovative Therapies
5.6.1. Company Overview
5.6.2. Neoantigen Targeted Therapies Portfolio
5.6.3. Recent Collaborations
Press
Release: Variation 2 (Format 3)
5.6.4. Future Outlook
5.7. Iovance Biotherapeutics
5.7.1. Company Overview
5.7.2. Financial Information
5.7.3. Neoantigen Targeted Therapies Portfolio
5.7.4. Recent Collaborations
5.7.5. Future Outlook
5.8. MediGene
5.8.1. Company Overview
5.8.2. Financial Information
5.8.3. Neoantigen Targeted Therapies Portfolio
5.8.4. Recent Collaborations
5.8.5. Future Outlook
5.9. Neon Therapeutics
5.9.1. Company Overview
5.9.2. Financial Information
5.9.3. Neoantigen Targeted Therapies Portfolio
5.9.4. Recent Collaborations
5.9.5. Future Outlook
6. PUBLICATION
ANALYSIS
6.1. Chapter Overview
6.2. Methodology
6.3. Neoantigen Targeted Therapies: List of
Publications
6.3.1. Analysis by Year of Publication
6.3.2. Analysis by Type of Study
6.3.3. Analysis by Study Objective
6.3.4. Analysis by Affiliated Therapies
6.3.5. Analysis by Target Disease Indication
6.3.6. Key Journals: Analysis by Number of
Publications
7. PATENT
ANALYSIS
7.1. Chapter Overview
7.2.
Scope and Methodology
7.3.
Neoantigen Targeted Therapies: Patent
Analysis
7.3.1.
Analysis by Publication Year
7.3.2.
Analysis by Geographical Location
7.3.3.
Analysis by CPC Classifications
7.3.4. Analysis by Type of Industry
7.3.5. Emerging Focus Areas
7.3.6. Leading Players: Analysis by Number of
Patents
7.4.
Neoantigen Targeted Therapies: Patent
Benchmarking Analysis
7.4.1. Analysis by Patent Characteristics
7.5.
Neoantigen Targeted Therapies: Patent
Valuation Analysis
8. PARTNERSHIPS
AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Neoantigen Targeted Therapies: List of
Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
Press
Release: Variation 2 (Format 3)
8.3.3. Analysis
by Type of Immunotherapy
8.3.4. Analysis by Type of Partnership and Type of
Product
8.3.5. Analysis by Type of Partnership and Target
Disease Indication
8.3.6. Regional Analysis
8.3.7. Most Active Players: Analysis by Number of
Partnerships
9. FUNDING AND
INVESTMENT ANALYSIS
9.1. Chapter Overview
9.2. Types of Funding
9.3. Neoantigen Targeted Therapies: Funding and
Investment Analysis
9.3.1. Analysis by Number of Instances
9.3.2. Analysis by Amount Invested
9.3.3. Analysis by Type of Funding
9.3.4. Analysis by Amount Invested across Different
Types of Therapies
9.3.5. Analysis by Amount Invested across Different
Types of Indications
9.3.4. Analysis by Geography
9.3.5. Most Active Players: Analysis by Amount of
Funding
9.3.6. Most Active Investors: Analysis by Number of
Instances
9.4. Concluding Remarks
10. MARKET
FORECAST AND OPPORTUNITY ANALYSIS
10.1 Chapter Overview
10.2. Key Assumptions and Forecast Methodology
10.3. Global Neoantigen Targeted Therapies
Market, 2019-2030
10.3.1. Global Neoantigen Targeted Therapies Market:
Distribution by Region, 2019-2030 (USD Million)
10.3.2. Global Neoantigen Targeted Therapies Market: Distribution by Target
Disease Indication, 2019-
2030 (USD Million)
10.3.2.1Global
Neoantigen Targeted Therapies Market for Bone and Cartilage Cancer, 2019-
2030 (USD Million)
10.3.2.2.Global
Neoantigen Targeted Therapies Market for Colorectal Cancer, 2019-2030
10.3.2.3.Global
Neoantigen Targeted Therapies Market for Gynecological Cancers, 2019-2030 (USD
Million)
10.3.2.4.Global
Neoantigen Targeted Therapies Market for Head and Neck Cancer, 2019-2030 (USD
Million)
10.3.2.5.Global
Neoantigen Targeted Therapies Market for Hepatocellular Carcinoma, 2019-2030
(USD
Million)
10.3.2.6.Global
Neoantigen Targeted Therapies Market for Lung Cancer, 2019-2030 (USD Million)
10.3.2.7.Global
Neoantigen Targeted Therapies Market for Renal Carcinoma, 2019-2030 (USD
Million)
10.3.2.8.Global
Neoantigen Targeted Therapies Market for Other Cancers, 2019-2030 (USD Million)
10.3.3.Global
Neoantigen Targeted Therapies Market: Distribution by Type of Neoantigen,
2019-2030
(USD Million)
10.3.3.1.Global
Neoantigen Targeted Therapies Market for Personalized Neoantigen Targeted
Therapies, 2019-2030 (USD Million)
10.3.3.2.Global
Neoantigen Targeted Therapies Market for Off-the-shelf Neoantigen Targeted
Therapies,
2019-2030 (USD Million)
10.3.4. Global Neoantigen Targeted Therapies Market: Distribution by Type
of Immunotherapy, 2019-2030 (USD Million)
10.3.4.1.Global
Neoantigen Targeted Therapies Market for Dendritic Cell Vaccines, 2019-2030
(USD
Million)
10.3.4.2.Global
Neoantigen Targeted Therapies Market for DNA / RNA-based Vaccines, 2019-2030
(USD Million)
10.3.4.3.Global
Neoantigen Targeted Therapies Market for Protein / Peptide-based Vaccines,
2019-2030
(USD Million)
Press
Release: Variation 2 (Format 3)
10.3.4.4.Global
Neoantigen Targeted Therapies Market for TIL-based Therapies, 2019-2030 (USD
Million)
10.3.5. Global Neoantigen Targeted Therapies Market: Distribution by Route
of Administration, 2019-2030 (USD Million)
10.3.5.1.Global
Neoantigen Targeted Therapies Market for Intradermal Route of Administration,
2019-
2030 (USD Million)
10.3.5.2.Global
Neoantigen Targeted Therapies Market for Intravenous Route of Administration,
2019-
2030 (USD Million)
10.3.5.3.Global
Neoantigen Targeted Therapies Market for Subcutaneous Route of Administration,
2019-
2030 (USD Million)
10.3.5.4.Global
Neoantigen Targeted Therapies Market for Other Routes of Administration,
2019-2030
(USD Million)
10.4. Neoantigen Targeted Therapies Market in the
US, 2019-2030 (USD Million)
10.4.1. Neoantigen Targeted Therapies Market in the US: Distribution by
Target Disease Indication, 2019-2030 (USD Million)
10.4.2. Neoantigen Targeted Therapies Market in the US: Distribution by
Type of Neoantigen, 2019-2030 (USD Million)
10.4.3. Neoantigen Targeted Therapies Market in the US: Distribution by
Type of Immunotherapy, 2019-2030 (USD Million)
10.4.3. Neoantigen Targeted Therapies Market in the US: Distribution by
Route of Administration, 2019-2030 (USD Million)
10.5. Neoantigen Targeted Therapies Market in the
UK, 2019-2030 (USD Million)
10.5.1. Neoantigen Targeted Therapies Market in the UK: Distribution by
Target Disease Indication, 2019-2030 (USD Million)
10.5.2. Neoantigen Targeted Therapies Market in the UK: Distribution by
Type of Neoantigen, 2019-2030 (USD Million)
10.5.3. Neoantigen Targeted Therapies Market in the UK: Distribution by
Type of Immunotherapy, 2019-2030 (USD Million)
10.5.4. Neoantigen Targeted Therapies Market in the UK: Distribution by
Route of Administration, 2019-2030 (USD Million)
10.6. Neoantigen Targeted Therapies Market in
Germany, 2019-2030 (USD Million)
10.6.1. Neoantigen Targeted Therapies Market in Germany: Distribution by
Target Disease Indication, 2019-2030 (USD Million)
10.6.2. Neoantigen Targeted Therapies Market in Germany: Distribution by
Type of Neoantigen, 2019-2030 (USD Million)
10.6.3. Neoantigen Targeted Therapies Market in Germany: Distribution by
Type of Immunotherapy, 2019-2030 (USD Million)
10.6.4. Neoantigen Targeted Therapies Market in Germany: Distribution by
Route of Administration, 2019-2030 (USD Million)
10.7. Neoantigen Targeted Therapies Market in
France, 2019-2030 (USD Million)
10.7.1. Neoantigen Targeted Therapies Market in France: Distribution by
Target Disease Indication, 2019-2030 (USD Million)
10.7.2. Neoantigen Targeted Therapies Market in France: Distribution by Type
of Neoantigen, 2019-2030 (USD Million)
10.7.3. Neoantigen Targeted Therapies Market in France: Distribution by
Type of Immunotherapy, 2019-2030 (USD Million)
10.7.4. Neoantigen Targeted Therapies Market in France: Distribution by
Route of Administration, 2019-2030 (USD Million)
10.8. Neoantigen Targeted Therapies Market in
Italy, 2019-2030 (USD Million)
Press
Release: Variation 2 (Format 3)
10.8.1. Neoantigen Targeted Therapies Market in Italy: Distribution by
Target Disease Indication, 2019-2030 (USD Million)
10.8.2. Neoantigen Targeted Therapies Market in Italy: Distribution by Type
of Neoantigen, 2019-2030 (USD Million)
10.8.3. Neoantigen Targeted Therapies Market in Italy: Distribution by Type
of Immunotherapy, 2019-2030 (USD Million)
10.8.4. Neoantigen Targeted Therapies Market in Italy: Distribution by
Route of Administration, 2019-2030 (USD Million)
10.9. Neoantigen Targeted Therapies Market in
Spain, 2019-2030 (USD Million)
10.9.1. Neoantigen Targeted Therapies Market in Spain: Distribution by
Target Disease Indication, 2019-2030 (USD Million)
10.9.2. Neoantigen Targeted Therapies Market in Spain: Distribution by Type
of Neoantigen, 2019-2030 (USD Million)
10.9.3. Neoantigen Targeted Therapies Market in Spain: Distribution by Type
of Immunotherapy, 2019-2030 (USD Million)
10.9.4. Neoantigen Targeted Therapies Market in Spain: Distribution by
Route of Administration, 2019-2030 (USD Million)
10.10. Neoantigen Targeted Therapies Market in Rest
of the World, 2019-2030 (USD Million)
10.10.1.Neoantigen
Targeted Therapies Market in Rest of the World: Distribution by Target Disease
Indication, 2019-2030 (USD Million)
10.10.2.Neoantigen
Targeted Therapies Market in Rest of the World: Distribution by Type of
Neoantigen,
2019-2030 (USD Million)
10.10.3.Neoantigen
Targeted Therapies Market in Rest of the World: Distribution by Type of
Immunotherapy, 2019-2030 (USD Million)
10.10.4.Neoantigen
Targeted Therapies Market in Rest of the World: Distribution by Route of
Administration, 2019-2030 (USD Million)
11. CONCLUDING
REMARKS
12. EXECUTIVE
INSIGHTS
12.1. Chapter Overview
12.2. AIVITA Biomedical
12.2.1. Company Snapshot
12.2.2. Interview Transcript: Gabriel Nistor (Chief
Scientific Officer)
12.3. BioLineRx
12.3.1. Company Snapshot
12.3.2. Interview Transcript: Ella Sorani (Vice
President Research and Development)
12.3. VAXIMM
12.3.1. Company Snapshot
12.3.2. Interview Transcript: Heinz Lubenau (Chief
Operating Officer and Co-Founder)
13. APPENDIX 1:
TABULATED DATA
14. APPENDIX 2:
LIST OF COMPANIES AND ORGANIZATIONS
Contact Details:
Gaurav
Chaudhary
+1 (415) 800 3415
